Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Enhancement of tumor response to chemotherapy by activation of the asmase/ceramide pathway through timed administration of a short-acting anti-angiogenic agent

Enhancement of tumor response to chemotherapy by activation of the asmase/ceramide pathway through timed administration of a short-acting anti-angiogenic agent

US Patent 11285137 · Granted Mar 29, 2022

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Perfusion modulated tumor dose sculpting with single dose radiotherapy2025
Perfusion modulated tumor dose sculpting with single dose radiotherapy2025
Methods for treating GI syndrome and graft versus host disease2024
Enhancement of tumor response to chemotherapy by activation of the asmase/cerami2024
Enhancement of tumor response to chemotherapy by activation of the asmase/cerami2024
Enhancement of tumor response to chemotherapy by activation of the asmase/cerami2024
Enhancement of tumor response to chemotherapy by activation of the asmase/cerami2024
Anti-ceramide antibodies2022
Methods for treating GI syndrome and graft versus host disease2021
Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibod2021
Methods for treating GI syndrome and graft versus host disease2020
Fucoidan nanogels and methods of their use and manufacture2019